-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on UroGen Pharma, Lowers Price Target to $3

Benzinga·05/22/2025 14:25:29
Listen to the news
Goldman Sachs analyst Paul Choi maintains UroGen Pharma (NASDAQ:URGN) with a Neutral and lowers the price target from $16 to $3.